BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06673667 (KT621 in moderate-to-severe atopic dermatitis): BVCT ex-ante prediction vs. reported outcome

On 26 Mar 2025, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 28 Mar 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially insufficient.

Clinical Trial

NCTID
NCT06673667
Drug Name
KT621
Drug MoA
E3ligase-binding STAT6 degrader
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
moderate-to-severe atopic dermatitis
Human Patients
118
Sponsor
Kymera Therapeutics
Phase
Phase 1

Prediction of , index 1823

Prospective Prediction
Prediction Index
1823
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in EASI75 at most slightly superior to dupilumab and inferior to upadacitinib)
Technical Prediction
partial SUCCESS (statistically significant yet weak clinical benefit in EASI75 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
367 days in advance
Readout Data Interpretation
KT621 achieved mean 29% EASI75 from baseline at day 28, which is slightly inferior to 38% EASI75 from baseline at week 4 by dupilumab and strongly inferior to 70% EASI75 from baseline at week 4 by upadacitinib (see add'l link below); well tolerated with no SAEs or treatment-related AEs
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-621 in Healthy Adult Participants
Phase
Phase 1
Status
Completed
Enrollment
118
Lead sponsor
Kymera Therapeutics, Inc.
Conditions
Healthy Participants Study
Interventions
DRUG: KT-621; DRUG: Placebo
Design
Randomized · Sequential · Double
Primary purpose
Other
Start
2024-10-22
Primary completion
2025-04-23
Completion
2025-04-23
Primary outcomes
  • Incidence of adverse events (From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD))
  • Treatment-emergent potentially clinically-significant abnormalities in safety laboratory parameters: hematology (From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD))
  • Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistry (From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD))
  • Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation (From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD))
  • Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds) (From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD))

NCT06673667 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials